Open Enrollment Commences for Phase 1b/2 Study Evaluating Ampligen in Combination with Imfinzi for the Treatment of Pancreatic Cancer

OCALA, Fla., Jan. 10, 2024. AIM ImmunoTech Inc. (“AIM” or the“Company”) today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials